RxDoctor Payments Data

Lori Hanes, MD

Family Medicine · Wichita Falls, TXNPI 1942200456

Payments from drug & device makers

$1,649in general payments, 2019–2025

Across 92 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241
  • Pfizer$226
  • AbbVie$206
  • Lilly USA, LLC$169
  • AstraZeneca$164
  • GSK$108
  • plus $535 from 14 others

What the payments were for

  • Food & beverage$1,649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,649 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$154,986
Medicare patients
413
Services billed
1,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$116,957
JardianceEmpagliflozin49$65,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$58,429
MounjaroTirzepatide36$56,178
EliquisApixaban46$43,952
MyrbetriqMirabegron30$29,967
JanuviaSitagliptin Phosphate16$22,696
FarxigaDapagliflozin Propanediol14$18,486
Breo ElliptaFluticasone/Vilanterol29$12,807
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$10,064
LinzessLinaclotide16$9,018
Serevent DiskusSalmeterol Xinafoate13$5,321
Levothyroxine Sodium388$4,343
Solifenacin Succinate83$3,179
Duloxetine Hcl148$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$241$116,957109 claims
GSKTrelegy Ellipta, Breo Ellipta$108$71,23694 claims
Boehringer IngelheimJardiance$40$65,92949 claims
Lilly USA, LLCMounjaro$169$56,17836 claims
PfizerEliquis$226$43,95246 claims
Astellas Pharma US IncMyrbetriq$41$29,96730 claims
AstraZenecaFarxiga$164$18,48614 claims
AbbVieLinzess, Synthroid$206$10,38448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →